“Real‑time visibility into manufacturing would enable faster optimization, improved robustness, and more responsive control strategies, ultimately helping unlock the full potential of advanced AAV production platforms.” Ashling Cannon, Editor, Cell & Gene Therapy Insights , speaks with Pranav Joshi, Associate Director, Upstream CMC Sciences, GEMMA Biotherapeutics, USA, about the evolving mechanics of AAV upstream manufacturing, the continued role of transient systems, and how process biology, platform strategy and analytical technologies may shape the next generation of viral vector production.
Pranav Joshi (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: